Live from the NIH registry
Studies recruiting near Fort Worth right now
Top 25 of 609 recruiting studies, sorted by proximity — each links to its official registry page
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Cytomegalovirus (CMV)
Phase 3
Interventional 80 participants sought
Cook Children's Health Care System — Fort Worth, Texas (4.2 mi)
· Sponsor: Takeda
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10301, Fort Worth, TX — Fort Worth, Texas (4.2 mi)
· Sponsor: Colorado Prevention Center
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Cook Children's Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
Phase 1
Interventional 572 participants sought
NEXT Dallas — Irving, Texas (23.3 mi)
· Sponsor: ArriVent BioPharma, Inc.
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Complex Regional Pain Syndrome Type I
Phase 3
Interventional 270 participants sought
Ambros Clinical Trial Site — Fort Worth, Texas (4.2 mi)
· Sponsor: Ambros Therapeutics, Inc.
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Diabetic Macular Edema
Phase 1, Phase 2
Interventional 49 participants sought
Strategic Clinical Research Group — Willow Park, Texas (17.7 mi)
· Sponsor: Boehringer Ingelheim
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: SWOG Cancer Research Network
RA-PRO PRAGMATIC TRIAL
Rheumatoid Arthritis
Phase 3
Interventional 924 participants sought
Heritage Rheumatology and Arthritis Care — Colleyville, Texas (13.1 mi)
· Sponsor: University of Alabama at Birmingham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1
Interventional 694 participants sought
Next Oncology Dallas /ID# 276254 — Irving, Texas (23.3 mi)
· Sponsor: AbbVie
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Phase 3
Interventional 428 participants sought
UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: NRG Oncology
PAS-004 in Patients With Advanced Solid Tumors
RAS Mutation, NF1 Mutation
Phase 1
Interventional 48 participants sought
NEXT Oncology — Irving, Texas (23.3 mi)
· Sponsor: Pasithea Therapeutics Corp.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Research Site — Fort Worth, Texas (4.2 mi)
· Sponsor: AstraZeneca
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Phase 3
Interventional 450 participants sought
Sl0044 50673 — Fort Worth, Texas (4.2 mi)
· Sponsor: UCB Biopharma SRL
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Phase 1
Interventional 364 participants sought
NEXT Oncology Dallas — Irving, Texas (23.3 mi)
· Sponsor: Astellas Pharma Inc
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities
Periprosthetic Joint Infections
N/A
Interventional 204 participants sought
Carrollton regional Medical Center — Carrollton, Texas (29.1 mi)
· Sponsor: Elute, Inc.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
Phase 3
Interventional 800 participants sought
Research Site — Fort Worth, Texas (4.2 mi)
· Sponsor: AstraZeneca
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 1,145 participants sought
Research Site — Flower Mound, Texas (21.7 mi)
· Sponsor: AstraZeneca
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Colitis, Ulcerative
N/A
Observational 300 participants sought
GI Alliance Research — Southlake, Texas (16.6 mi)
· Sponsor: Pfizer
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Phase 1, Phase 2
Interventional 460 participants sought
Texas Oncology - DFW ( Site 8000) — Fort Worth, Texas (4.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Phase 3
Interventional 599 participants sought
North Hills Medical Research Inc — Bedford, Texas (12.6 mi)
· Sponsor: Novartis Pharmaceuticals
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
University of Texas Southwestern Simmons Cancer Center - Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: Pfizer
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Advanced-stage Solid Tumors
Phase 1
Interventional 360 participants sought
NEXT Oncology — Irving, Texas (23.3 mi)
· Sponsor: Janssen Research & Development, LLC
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Medulloblastoma
Phase 2
Interventional 130 participants sought
Cook Children's Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: St. Jude Children's Research Hospital